UCB SA
60 Allée De La Recherche, Anderlecht, BRUXELLES 1070
Related Posts:
September 17, 2025
UCB, a biopharmaceutical company based in Brussels, has released new three-year data from its BE HEARD trials for BIMZELX (bimekizumab) in patients with moderate to severe hidradenitis suppurativa (HS).
Read more →September 17, 2025
UCB has released new long-term data from its Phase 3 trials for BIMZELX (bimekizumab), a treatment for moderate-to-severe plaque psoriasis.
Read more →January 7, 2025
UCB has announced an upgrade to its 2025 financial guidance, citing strong performance from its key products and ongoing efforts to streamline its portfolio.
Read more →January 3, 2024
UCB, a global biopharmaceutical company based in Brussels, presented its growth strategy and financial outlook at the 44th Annual J.P. Morgan Healthcare Conference.
Read more →
Sign-up for the Weekly Newsletter from EU Business Daily.